Rheumatoid Arthritis

You have full text access to this OnlineOpen article

The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom

  1. Allison L. Smitten1,†,
  2. Hyon K. Choi2,7,8,‡,
  3. Marc C. Hochberg3,§,
  4. Samy Suissa4,¶,
  5. Teresa A. Simon5,
  6. Marcia A. Testa1,
  7. K. Arnold Chan6,9,*

Article first published online: 29 NOV 2007

DOI: 10.1002/art.23112

Issue

Arthritis Care & Research

Arthritis Care & Research

Volume 57, Issue 8, pages 1431–1438, 15 December 2007

Additional Information

How to Cite

Smitten, A. L., Choi, H. K., Hochberg, M. C., Suissa, S., Simon, T. A., Testa, M. A. and Chan, K. A. (2007), The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis & Rheumatism, 57: 1431–1438. doi: 10.1002/art.23112

Author Information

  1. 1

    Harvard School of Public Health, Boston, Massachusetts

  2. 2

    Arthritis Research Centre of Canada

  3. 3

    University of Maryland School of Medicine, Baltimore

  4. 4

    McGill University Health Centre, Montreal, Quebec, Canada

  5. 5

    Global Pharmacovigilence and Epidemiology, Bristol-Myers Squibb Company, Hopewell, New Jersey

  6. 6

    Harvard School of Public Health, Boston, Massachusetts

  7. 7

    Vancouver General Hospital, University of British Columbia, Vancouver, British Columbia, Canada

  8. 8

    Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts

  9. 9

    i3DrugSafety, Auburndale, Massachusetts

  1. †

    Dr. Smitten has received consultant fees (more than $10,000) from Bristol-Myers Squibb.

  2. ‡

    Dr. Choi serves on the safety monitoring board for a clinical trial by Centocor.

  3. §

    Dr. Hochberg has received consultant fees (less than $10,000) from Bristol-Myers Squibb.

  4. Dr. Suissa has received consultant fees (less than $10,000 each) from Bristol-Myers Squibb and Sanofi-Aventis.

*Department of Epidemiology, Harvard School of Public Health, 677 Huntington Avenue, Boston, MA 02115

Publication History

  1. Issue published online: 29 NOV 2007
  2. Article first published online: 29 NOV 2007
  3. Manuscript Accepted: 4 JUN 2007
  4. Manuscript Received: 6 OCT 2006

Funded by

  • Harvard Pharmacoepidemiology Program
  • Bristol-Myers Squibb Company

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (89K)

REFERENCES

  • 1
    Choo PW, Donahue JG, Manson JE, Platt R. The epidemiology of varicella and its complications. J Infect Dis 1995; 172: 706–12.
  • 2
    Gnann JW Jr, Whitley RJ. Clinical practice: herpes zoster. N Engl J Med 2002; 347: 340–6.
  • 3
    Hope-Simpson RE. The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med 1965; 58: 9–20.
  • 4
    Schmader K. Herpes zoster in older adults. Clin Infect Dis 2001; 32: 1481–6.
  • 5
    Thomas SL, Hall AJ. What does epidemiology tell us about risk factors for herpes zoster? Lancet Infect Dis 2004; 4: 26–33.
  • 6
    Dolin R, Reichman RC, Mazur MH, Whitley RJ. NIH conference: herpes zoster-varicella infection in immunosuppressed patients. Ann Intern Med 1978; 89: 375–88.
  • 7
    Straus SE, Ostrove JM, Inchauspe G, Felser JM, Freifeld A, Croen KD, et al. NIH conference. Varicella-zoster virus infections: biology, natural history, treatment and prevention [published erratum appears in Ann Intern Med 1988;109:438–9]. Ann Intern Med 1988; 108: 221–7.
  • 8
    Gilden DH, Kleinschmidt-DeMasters BK, LaGuardia JJ, Mahalingam R, Cohrs RJ. Neurologic complications of the reactivation of varicella-zoster virus [published erratum appears in N Engl J Med 2000;342:1063]. N Engl J Med 2000; 342: 635–45.
  • 9
    Koetz K, Bryl E, Spickschen K, O'Fallon WM, Goronzy JJ, Weyand CM. T cell homeostasis in patients with rheumatoid arthritis. Proc Natl Acad Sci U S A 2000; 97: 9203–8.
  • 10
    Dobloug JH, Forre O, Kvien TK, Egeland T, Degre M. Natural killer (NK) cell activity of peripheral blood, synovial fluid, and synovial tissue lymphocytes from patients with rheumatoid arthritis and juvenile rheumatoid arthritis. Ann Rheum Dis 1982; 41: 490–4.
  • 11
    Fox RI, Fong S, Tsoukas C, Vaughan JH. Characterization of recirculating lymphocytes in rheumatoid arthritis patients: selective deficiency of natural killer cells in thoracic duct lymph. J Immunol 1984; 132: 2883–7.
  • 12
    Antonelli MA, Moreland LW, Brick JE. Herpes zoster in patients with rheumatoid arthritis treated with weekly, low-dose methotrexate. Am J Med 1991; 90: 295–8.
  • 13
    Hernandez-Cruz B, Cardiel MH, Villa AR, Alcocer-Varela J. Development, recurrence and severity of infections in Mexican patients with rheumatoid arthritis: a nested case-control study. J Rheumatol 1998; 25: 1900–7.
  • 14
    Van der Veen MJ, van der Heide A, Kruize AA, Bijlsma JW. Infection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate. Ann Rheum Dis 1994; 53: 224–8.
  • 15
    Kupperman HG, Davis JS, Bartfeld H. Herpes zoster during cortisone therapy in three patients with rheumatoid arthritis. N Y State J Med 1952; 52: 1915–6.
  • 16
    Eckhardt WF, Hebard GW. Severe herpes zoster during corticosteroid therapy: report of a severe attack in a patient with rheumatoid arthritis. Arch Intern Med 1961; 108: 594–8.
  • 17
    Fam AG, Paton TW, Cowan DH. Herpes zoster during gold therapy [letter]. Ann Intern Med 1981; 94: 712–3.
  • 18
    Anderson DJ, Janoff EN. Herpes zoster infection in a patient with methotrexate given prednisone to prevent post-herpetic neuralgia [letter]. Ann Intern Med 1987; 107: 783.
  • 19
    Ching DW. Severe, disseminated, life threatening herpes zoster infection in a patient with rheumatoid arthritis treated with methotrexate [letter]. Ann Rheum Dis 1995; 54: 155.
  • 20
    Golden HE. Herpes zoster encephalomyelitis in a patient with rheumatoid arthritis treated with low dose methotrexate [letter]. J Rheumatol 1997; 24: 2487–8.
  • 21
    Lyon CC, Thompson D. Herpes zoster encephalomyelitis associated with low dose methotrexate for rheumatoid arthritis. J Rheumatol 1997; 24: 589–91.
  • 22
    Campalani E, Meenagh GK, Finch MB. Case number 22: an interesting case of herpes zoster in rheumatoid arthritis. Ann Rheum Dis 2002; 61: 102.
  • 23
    Kinder A, Stephens S, Mortimer N, Sheldon P. Severe herpes zoster after infliximab infusion. Postgrad Med J 2004; 80: 26.
  • 24
    Wolfe F, Michaud K, Chakravarty EF. Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders. Rheumatology (Oxford) 2006; 45: 1370–5.
  • 25
    Suissa S. Novel approaches to pharmacoepidemiology study design and statistical analysis. In: StromBL, editor. Pharmacoepidemiology. 3rd ed. New York: John Wiley & Sons; 2000. p. 785–805.
  • 26
    Delea TE, Edelsberg JS, Hagiwara M, Oster G, Phillips LS. Use of thiazolidinediones and risk of heart failure in persons with type 2 diabetes: a retrospective cohort study. Diabetes Care 2003; 26: 2983–9.
  • 27
    Suissa S, Ernst P, Hudson M, Bitton A, Kezouh A. Newer disease-modifying antirheumatic drugs and the risk of serious hepatic adverse events in patients with rheumatoid arthritis. Am J Med 2004; 117: 87–92.
  • 28
    Jick SS, Kaye JA, Russmann S, Jick H. Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel. Contraception 2006; 73: 566–70.
  • 29
    Arellano FM, Wentworth CE, Arana A, Fernandez C, Paul CF. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol 2007; 127: 808–16.
  • 30
    Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ 1991; 302: 766–8.
  • 31
    Jick H, Terris BZ, Derby LE, Jick SS. Further validation of information recorded on a general practitioner based computerised data resource in the United Kingdom. Pharmacoepidemiol Drug Saf 1992; 1: 347–9.
    Direct Link:
  • 32
    Hollowell J. General practice research database: scope and quality of data. London: Office for Population Censuses and Surveys; 1994.
  • 33
    Jick SS, Kaye JA, Vasilakis-Scaramozza C, Garcia Rodriguez LA, Ruigomez A, Meier CR, et al. Validity of the general practice research database. Pharmacotherapy 2003; 23: 686–9.
  • 34
    Garcia Rodriguez LA, Perez Gutthann S. Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol 1998; 45: 419–25.
    Direct Link:
  • 35
    Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002; 46: 2287–93.
    Direct Link:
  • 36
    Mitchell DM, Spitz PW, Young DY, Bloch DA, McShane DJ, Fries JF. Survival, prognosis, and causes of death in rheumatoid arthritis. Arthritis Rheum 1986; 29: 706–14.
    Direct Link:
  • 37
    Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA, et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994; 37: 481–94.
    Direct Link:
  • 38
    Symmons DP, Jones MA, Scott DL, Prior P. Longterm mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well. J Rheumatol 1998; 25: 1072–7.
  • 39
    Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Predictors of infection in rheumatoid arthritis. Arthritis Rheum 2002; 46: 2294–300.
    Direct Link:
  • 40
    Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 1989; 11: 954–63.
  • 41
    Listing J, Strangfeld A, Kary S, Rau R, von Hinueber U, Stoyanova-Scholz M, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005; 52: 3403–12.
    Direct Link:
  • 42
    Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials [published erratum appears in JAMA 2006;295:2482]. JAMA 2006; 295: 2275–85.
  • 43
    Dixon WG, Watson K, Lunt M, Hyrich KL, British Society for Rheumatology Biologics Register Control Centre Consortium, Silman AJ, et al, on behalf of the British Society for Rheumatology Biologics Register. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti–tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006; 54: 2368–76.
    Direct Link:
  • 44
    Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti–tumor necrosis factor therapy. Arthritis Rheum 2006; 54: 628–34.
    Direct Link:
View Full Article (HTML) Get PDF (89K)